GlassScriptPhysician profile
Joseph H Yi
NPI 1861565285
$15,715.77
in general payments reported to CMS, 2019-2025
53 companies · $2,043 in 2025
The $2,043 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,438 · 2020: $2,182 · 2021: $2,435 · 2022: $2,069 · 2023: $2,594 · 2024: $1,954 · 2025: $2,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,527 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,526.59 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,889.65 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,818.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,773.70 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $1,517.02 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $1,039.07 | 2019-2025 | Linzess, Creon, Viberzi |
| Amgen INC. | $893.57 | 2019-2025 | Otezla, Repatha, Prolia |
| Astellas Pharma US INC | $717.68 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $566.80 | 2019-2021 | |
| Pfizer INC. | $553.85 | 2019-2024 | |
| Glaxosmithkline, LLC. | $432.44 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $384.33 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $356.51 | 2021-2025 | |
| Radius Health, INC. | $335.13 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $322.20 | 2024-2025 | Gardasil 9, Capvaxive, Verquvo |
| Exact Sciences Corporation | $276.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Yi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.